This week, the European Parliament’s Health Committee introduced amendments to Supplementary Protection Certificate (SPC) manufacturing waivers.
This week, the European Parliament’s Health Committee (ENVI) introduced amendments to Supplementary Protection Certificate (SPC) manufacturing waivers.
An SPC is an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The SPC is meant to offset the loss of patent protection that takes place during the development of a generic or biosimilar.
In May, the European Commission (EC) proposed revising SPCs in order to boost the development and manufacturing of biosimilars and generics. The proposal looked to introduce a manufacturing exemption for export purposes during the term of an SPC. The exemption would restrict the protection allowed by the SPC in order to remove competitive disadvantages to EU-based generic and biosimilar developers by allowing a drug maker to manufacture a product in an EU member state for the sole purpose of exporting a product to a non-EU market that is not subject to an SPC.
The current waiver also blocks the production and stockpiling of generics and biosimilars to allow for “day 1” launches after SPC expiry. Due to such restrictions, the EU pharmaceutical industry instead must delocalize production to non-EU countries such as Canada, India, China, and the United States.
In its most recently submitted amendments, ENVI “sent a clear signal of support with the adoption of a ‘day 1’ launch possibility to supply European patients with European manufactured medicines.” As the EU expects €90 billion (approximately $102 billion) worth of blockbuster medicines coming off patent in 2020, this amendment could have significant implications for industry.
ENVI additionally noted the need to protect trade secrets and commercially confidential information in the context of a procedure to notify other manufacturers of patent expiry. However, the committee also “maintained the very long lead time for implementing the waiver which will delay its ability to create manufacturing and access opportunities for many years.”
Adrian van den Hoven, director general of Medicines for Europe, commented in a statement, “We hope that this progress, together with a more reasonable date of application, will be agreed by the Parliament and the Council in a future final agreement. We urge the Parliament’s Legal Committee to adopt a final opinion that includes these important priorities for health, for jobs, and for a robust pharmaceutical ecosystem.”
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.